Lake Street raised the firm’s price target on Castle Biosciences (CSTL) to $40 from $34 and keeps a Buy rating on the shares. The firm, which notes that its 2025 revenue estimate is $267.3M, is raising its target after a Q3 beat to reflect better-than-expected testing volumes in several tests and multiple expansion.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CSTL: